Processing

Please wait...

Settings

Settings

Goto Application

1. WO2001045746 - METHODS AND COMPOSITIONS FOR PROLONGING ELIMINATION HALF-TIMES OF BIOACTIVE COMPOUNDS

Publication Number WO/2001/045746
Publication Date 28.06.2001
International Application No. PCT/US2000/035325
International Filing Date 22.12.2000
Chapter 2 Demand Filed 23.07.2001
IPC
A61K 38/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 47/48 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
48the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
C07K 7/08 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
08having 12 to 20 amino acids
C07K 14/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07K 16/22 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
22against growth factors
C07K 16/24 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 47/62
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
A61K 47/643
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
A61K 47/65
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Applicants
  • GENENTECH, INC. [US]/[US] (AllExceptUS)
  • DELANO, Warren, L. [US]/[US] (UsOnly)
  • DENNIS, Mark, S. [US]/[US] (UsOnly)
  • LOWMAN, Henry, B. [US]/[US] (UsOnly)
Inventors
  • DELANO, Warren, L.
  • DENNIS, Mark, S.
  • LOWMAN, Henry, B.
Agents
  • KUBINEC, Jeffrey, S.
  • WALTON, Sean, M
Priority Data
60/173,04824.12.1999US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHODS AND COMPOSITIONS FOR PROLONGING ELIMINATION HALF-TIMES OF BIOACTIVE COMPOUNDS
(FR) METHODES ET COMPOSITIONS PERMETTANT DE PROLONGER LES DEMI-VIES D'ELIMINATION DE COMPOSES BIOACTIFS
Abstract
(EN) Peptide ligands having affinity for IgG or for serum albumin are disclosed. Also disclosed are hybrid molecules comprising a peptide ligand domain and an active domain. The active domain may comprise any molecule having utility as a therapeutic or diagnostic agent. The hybrid molecules of the invention may be prepared using any of a number techniques including production in and purification from recombinant organisms transformed or transfected with an isolated nucleic acid encoding the hybrid molecule, or by chemical synthesis of the hybrid. The hybrid molecules have utility as agents to alter the elimination half-times of active domain molecules. Elimination half-time is altered by generating a hybrid molecule of the present invention wherein the peptide ligand has binding affinity for a plasma protein. In a preferred embodiment, a bioactive molecule having a short elimination half-time is incorporated as or into an active domain of the hybrid molecules of the invention, and the binding affinity of the peptide ligand domain prolongs the elimination half-time of the hybrid as compared to that of the bioactive molecule.
(FR) L'invention concerne des ligands peptidiques présentant une affinité pour l'IgG ou pour l'albumine sérique. L'invention concerne également des molécules hybrides comprenant un domaine de ligand peptidique et un domaine actif. Le domaine actif peut comprendre toute molécule pouvant servir d'agent thérapeutique ou diagnostique. Les molécules hybrides de l'invention peuvent être préparées à l'aide d'un certain nombre de techniques, y compris la production et la purification à partir d'organismes de recombinaison transformés ou transfectés avec un acide nucléique isolé codant pour la molécule hybride, ou par synthèse chimique de l'hybride. Les molécules hybrides servent d'agents destinés à modifier les demi-vies d'élimination des molécules à domaine actif. La demi-vie d'élimination est modifiée par la génération d'une molécule hybride de la présente invention dans laquelle le ligand peptidique posséde une affinité de liaison pour une protéine plasmatique. Dans un mode de réalisation préféré, une molécule bioactive possédant une courte demi-vie d'élimination est incorporée comme ou dans un domaine actif des molécules hybrides de l'invention, et l'affinité de liaison du domaine de ligand peptidique prolonge la demi-vie d'élimination de l'hybride en comparaison avec celle de la molécule bioactive.
Latest bibliographic data on file with the International Bureau